{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3808, 
        3817
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3942, 
        3958
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3158, 
        3166
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3731, 
        3746
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3748, 
        3752
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3232, 
        3247
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3791, 
        3799
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3753, 
        3759
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3800, 
        3807
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3761, 
        3770
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 9^9999^MOH|PIMS|CCO|20160601235559|8E5E3F25058D009336038E9DC2218C0B6D3D0671|ORU^R01|9999999999999|P|2.5||||||\nPID|1||N999999999^^^^CMR^HOSPITAL 9&9999&MOH~N999999999^^^^MRN^HOSPITAL 9&9999&MOH~9999999999&CX&ON^^^^JHN||XXXX^XXXXXXX^ XXXXX^^^^||99999999|F|||9999 XXXXXXXXXX XX X^999^XXXXXXXX^XX^X9X 9X9^999|||||||||||||||||||N|||\nOBR|1||S16-13624|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160527|||60903^XXXXXXXXXXX^XXXXXX^^^^||||||||||||20160601|||C|||||||99999^XXXXXX^XXXXXXXXX^^^^|||||||\n\n\n\n\n\n\n\nADDENDUMS\n\nESTROGEN AND PROGESTERONE RECEPTOR PROTEIN IMMUNOHISTOCHEMISTRY\nDIAGNOSIS:\nINVASIVE CARCINOMA:\n- POSITIVE FOR ESTROGEN RECEPTORS\n- LOW POSITIVE FOR PROGESTERONE RECEPTORS\nRESULT:\n(Block A1)\n100% of cell nuclei are positive for estrogen receptors\n5% of cell nuclei are dim positive for progesterone receptors\nAntibody used:\nEstrogen receptor (Rabbit monoclonal, Clone SP1, Ventana)\nProgesterone receptor (Rabbit Monoclonal, Clone 1E2, Ventana)\nPositive and negative external laboratory controls stained appropriately.\n\nThreshold for interpretation of Estrogen and Progesterone\nreceptors as per CCO guidelines:\nPOSITIVE: 10% or more of tumor cell nuclei stain positively with any intensity\nLOW POSITIVE: 1-9% of tumor cell nuclei stain positively with any intensity\nNEGATIVE: <1% of tumor cell nuclei stain positively with any intensity\nReference:\nDiaz LK, Sneige N: Estrogen receptor analysis for breast cancer: current\nissues and keys to increasing testing accuracy. Adv Anat Pathol\n2005;12:10-19\nIMMUNOHISTOCHEMICAL STUDIES FOR HER2 ONCOPROTEIN:\nRESULTS:\n   BREAST, LEFT, CORE BIOPSY:\n        INVASIVE MAMMARY CARCINOMA.\n        NEGATIVE FOR HER2 ONCOPROTEIN OVEREXPRESSION.\nNote: Cold ischemia and fixation times meet the requirements specified in the\nlatest version of the ASCO/CAP guidelines: Yes\nStaining intensity: 0-1+\nBlock#: A1\nScoring Criterion and Scoring System:\nIHC 0 (Negative): No staining observed; or membrane staining that is incomplete\nand is faint/barely perceptible and within <=10% of the invasive tumor cells.\nIHC 1+ (Negative): Incomplete membrane staining that is faint/barely\nperceptible and within >10% of the invasive tumor cells.\nIHC 2+ (Equivocal): Circumferential membrane staining that is incomplete and/or\nweak/moderate and within >10% of the invasive tumor cells; or complete and\ncircumferential membrane staining that is intense and within <=10% of the\ninvasive tumor cells.\nIHC 3+ (Positive): Circumferential membrane staining that is complete, intense\nand within >10% of tumor cells.\nINDETERMINATE: Another specimen should be requested for testing to determine\nHER2 status if possible.\nMethodology:\nFixation Type: 10% neutral buffered formalin\nRecommended Length of Fixation: 6 - 72 hours\nRecommended Cold Ischemia time: < 1 hour\nAntibody used: c-erb-2/HER-2/neu (Clone 4B5 Rabbit monoclonal antibody, Ventana\nMedical Systems)\nControl Slides Examined: In-house known Her2 positive control tissue was\nevaluated along with the test tissue and shows appropriate staining.\nReferences:\nWolfe et al. ASCO/CAP HER2 Testing Guideline Update. J Clin Oncol\n2013:31:3997-4013\n\n\nCOMMENTS\n\nSpecimen: A\nExcision time: 1530\nTime placed in Formalin: 1530\n\n\nGROSS PATHOLOGY\n\nThe specimen is received in formalin, labeled with the patient's name and as \"LEFT BREAST 1 O'CLOCK\". The specimen consists of four\nfibrofatty core biopsies measuring 1.0 to 1.3 cm in length x 0.2 cm in diameter and\ntwo fragments of core biopsies measuring 0.1 to 0.3 cm entirely submitted in three\ncassettes, A1 and A2 two cores each and A3 two fragments, entirely submitted.\n                                        /SM\n\n\nTISSUE SUBMITTED\n\nBREAST BIOPSY (LEFT BREAST 1 O'CLOCK )\n\n\nFINAL DIAGNOSIS\n\nLEFT BREAST, 1 O'CLOCK, CORE BIOPSY:\n   -  INVASIVE MAMMARY CARCINOMA\n   -  HORMONE RECEPTORS AND HER2 STUDIES ARE PENDING; AN ADDENDUM WILL FOLLOW\n                                   (CODE 1)\n\n\nCLINICAL HISTORY\n\nRIGHT BREAST CANCER, NOW PALPABLE LUMP LEFT\n\n\n"
}